Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

CHEK1 and circCHEK1_246aa Promote Multiple Myeloma Malignancy By Evoking Chromosomal Instability and Bone Lesion

Ye Yang, PhD, Chunyan Gu, Wang Wang, Xiaozhu Tang

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-134206

Published: 2020

Journal Articles

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

Ye Yang, PhD, Mengjie Guo, Chunyan Gu

Blood (2019) 134 (Supplement_1): 3068.

https://doi.org/10.1182/blood-2019-127888

Published: 2019

Journal Articles

The Efficacy of a Novel Oral Proteasome Inhibitor NNU546 in Multiple Myeloma

Ye Yang, PhD, Yongqiang Zhu, Chunyan Gu

Blood (2019) 134 (Supplement_1): 5586.

https://doi.org/10.1182/blood-2019-127927

Published: 2019

Journal Articles

MK2 Is a Therapeutic Target for High-Risk Multiple Myeloma

Chunyan Gu, PhD, Hongbao Yang, Hailin Peng, Zhiye Xu, Ruini Chen, PhD, Ye Yang, PhD

Blood (2016) 128 (22): 5612.

https://doi.org/10.1182/blood.V128.22.5612.5612

Published: 2016

Journal Articles

Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence?

Dang Luan, MD, Karen Willard-Gallo, PhD, Soizic Garaud, PhD, Hugues Duvillier, Jean-Nicolas Lodewyckx, Cinzia Solinas, MD, Pushpamali De Silva, Chunyan Gu-Trantien, PhD, Catherine Sibille, MD PhD, Dominique Bron, MD PhD

Blood (2016) 128 (22): 5983.

https://doi.org/10.1182/blood.V128.22.5983.5983

Published: 2016

Journal Articles

FOXM1, CDK6 and Rb Dependent Drug Resistance and Senescence in Myeloma

Chunyan Gu, PhD, Ruini Chen, PhD, Xuefang Jing, PhD, Siegfried Janz, Ye Yang, PhD

Blood (2016) 128 (22): 4456.

https://doi.org/10.1182/blood.V128.22.4456.4456

Published: 2016

Journal Articles

Molecular profiling of CD3 − CD4 + T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways

Marie Ravoet, Catherine Sibille, Chunyan Gu, Myriam Libin, Benjamin Haibe-Kains, Christos Sotiriou, Michel Goldman, Florence Roufosse, Karen Willard-Gallo

Blood (2009) 114 (14): 2969–2983.

https://doi.org/10.1182/blood-2008-08-175091

Published: 2009

Includes: Supplemental data

NARROW

CHEK1 and circCHEK1_246aa Promote Multiple Myeloma Malignancy By Evoking Chromosomal Instability and Bone Lesion

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

The Efficacy of a Novel Oral Proteasome Inhibitor NNU546 in Multiple Myeloma

MK2 Is a Therapeutic Target for High-Risk Multiple Myeloma

Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence?

FOXM1, CDK6 and Rb Dependent Drug Resistance and Senescence in Myeloma

Molecular profiling of CD3 − CD4 + T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways

Email alerts

ASH Publications

American Society of Hematology

CHEK1 and circCHEK1_246aa Promote Multiple Myeloma Malignancy By Evoking Chromosomal Instability and Bone Lesion

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

The Efficacy of a Novel Oral Proteasome Inhibitor NNU546 in Multiple Myeloma

MK2 Is a Therapeutic Target for High-Risk Multiple Myeloma

Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence?

FOXM1, CDK6 and Rb Dependent Drug Resistance and Senescence in Myeloma

Molecular profiling of CD3 − CD4 + T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only